aqumeldi
proveca pharma limited - enalapril (maleate) - hjartabilun - lyf sem hafa áhrif á renín-angíótensín kerfið - treatment of heart failure.
veltassa
vifor fresenius medical care renal pharma france - kalsíumhýdrat sorbítak - blóðkalíumlækkun - lyf til meðferð kalíum og blóðfosfathækkun - veltassa er ætlað til meðferðar við blóðkalíumhækkun hjá fullorðnum.
neparvis
novartis europharm limited - sacubitril, valsartan - hjartabilun - lyf sem hafa áhrif á renín-angíótensín kerfið - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.
entresto
novartis europharm limited - sacubitril, valsartan - hjartabilun - ace ii hemla, önnur sturtu, umboðsmenn starfa á renín-ace kerfi - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
ramíl tafla 5 mg
teva b.v.* - ramiprilum inn - tafla - 5 mg
ramíl tafla 2,5 mg
teva b.v.* - ramiprilum inn - tafla - 2,5 mg
ramíl tafla 10 mg
teva b.v.* - ramiprilum inn - tafla - 10 mg
coversyl novum filmuhúðuð tafla 5 mg
les laboratoires servier* - perindoprilum arginín - filmuhúðuð tafla - 5 mg
darazíð tafla 20 mg/12,5 mg
actavis group ptc ehf. - enalaprilum maleat; hydrochlorothiazidum inn - tafla - 20 mg/12,5 mg
enalapril comp alvogen (enalapril comp ratiopharm) tafla 20 mg/12,5 mg
alvogen ehf. - enalaprilum maleat; hydrochlorothiazidum inn - tafla - 20 mg/12,5 mg